| Regulation of cancer stem cells in triple negative breast cancer N Fultang, M Chakraborty, B Peethambaran Cancer Drug Resistance 4 (2), 321, 2021 | 51 | 2021 |
| ROR1 regulates chemoresistance in Breast Cancer via modulation of drug efflux pump ABCB1 N Fultang, A Illendula, J Lin, MK Pandey, Z Klase, B Peethambaran Scientific reports 10 (1), 1821, 2020 | 43 | 2020 |
| Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity N Fultang, A Illendula, B Chen, C Wu, S Jonnalagadda, N Baird, Z Klase, ... PLoS One 14 (5), e0217789, 2019 | 36 | 2019 |
| A novel anti-triple negative breast cancer compound isolated from medicinal herb Myrothamnus flabellifolius J Brar, N Fultang, K Askey, MC Tettamanzi, B Peethambaran Journal of Medicinal Plants Research 12 (1), 7-14, 2018 | 18 | 2018 |
| Myeloid-derived suppressor cell differentiation in cancer: Transcriptional regulators and enhanceosome-mediated mechanisms N Fultang, X Li, T Li, YH Chen Frontiers in immunology 11, 619253, 2021 | 17 | 2021 |
| Retinoic acid induces differentiation in neuroblastoma via ROR1 by modulating retinoic acid response elements A Illendula, N Fultang, B Peethambaran Oncology Reports 44 (3), 1013-1024, 2020 | 10 | 2020 |
| Exogenous pre-harvest treatment with methyl jasmonate and chitosan elicits lycopene biosynthesis in tomato plants A Osano, N Fultang, J Davis J Environ Sci Eng 6, 561-568, 2017 | 5 | 2017 |
| Myrothamnus flabellifolius selectively targets Triple Negative Breast Cancer in vitro, restoring Tamoxifen Sensitivity through modulation of miRNAs associated with Estrogen … N Fultang, J Brar, I Mercier, Z Klase, B Peethambaran Int. j. appl. res. nat. prod 11 (1), 24-33, 2018 | 3 | 2018 |
| c-Rel-dependent monocytes are potent immune suppressor cells in cancer T Li, MJ Bou-Dargham, N Fultang, X Li, WS Pear, H Sun, YH Chen Journal of leukocyte biology 112 (4), 845-859, 2022 | 2 | 2022 |
| Wnt signaling in breast cancer oncogenesis, development and progression N Fultang, B Peethambaran Advances in Cancer Signal Transduction and Therapy. Bentham Science …, 2020 | 2 | 2020 |
| Combination of the MCL1 inhibitor PRT1419 and SMARCA2 degrader PRT3789 shows combinatorial benefit in SMARCA4 deleted lung cancer N Fultang, N Bhagwat, D Heiser, A Grego, M Hulse, V Thodima, K Ito, ... Cancer Research. Philadelphia, PA, USA: American Association for Cancer …, 2022 | 1 | 2022 |
| Abstract P5-07-13: MicroRNA-mediated restoration of tamoxifen sensitivity in triple negative breast cancer through modulation of estrogen receptor alpha/beta ratio using … N Fultang, Z Klase, I Mercier, B Peethambaran Cancer Research 78 (4_Supplement), P5-07-13-P5-07-13, 2018 | 1 | 2018 |
| Abstract PO5-27-07: A novel ROR1 inhibitor CPD86 suppresses Triple-Negative Breast Cancer cells via regulation of AKT/GSK3β pathway T Ta, V Reed, N Chandra, N Dwyer, N Fultang, S Gupta, I Singh, ... Cancer Research 84 (9_Supplement), PO5-27-07-PO5-27-07, 2024 | | 2024 |
| PRT2527, a novel highly selective cyclin-dependent kinase 9 (CDK9) inhibitor, has potent antitumor activity in combination with BTK and BCL2 inhibition in various lymphoid … N Fultang, AM Schwab, S McAneny-Droz, D Heiser, P Scherle, ... Cancer Research 84 (6_Supplement), 5966-5966, 2024 | | 2024 |
| PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer N Fultang, AM Schwab, S McAneny-Droz, A Grego, S Rodgers, BV Torres, ... Frontiers in Oncology 14, 2024 | | 2024 |
| Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers K Ito, M Hulse, A Agarwal, J Carter, M Sivakumar, K Vykuntam, M Wang, ... MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | | 2023 |
| Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers K Ito, M Hulse, A Agarwal, J Carter, M Sivakumar, K Vykuntam, M Wang, ... Molecular Cancer Therapeutics 22 (12_Supplement), B113-B113, 2023 | | 2023 |
| PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid … N Fultang, AM Schwab, S McAneny-Droz, D Heiser, PA Scherle, ... Blood 142 (Supplement 1), 5783-5783, 2023 | | 2023 |
| MCL1 inhibitor PRT1419 demonstrates anti-tumor activity in PBRM1-altered clear cell renal cancer and synergizes with standard of care agents N Fultang, B Vidal, AM Schwab, A Grego, D Heiser, K Vaddi, N Bhagwat, ... Cancer Research 83 (7_Supplement), 6147-6147, 2023 | | 2023 |
| SMARCA2 (BRM) degraders promotes differentiation and inhibit proliferation in AML models A Agarwal, OP Osinubi, K Vykuntam, N Fultang, N Bhagwat, D Heiser, ... Cancer Research 83 (7_Supplement), 1594-1594, 2023 | | 2023 |
